Assessment of PI-RADS v2 for the Detection of Prostate Cancer
- PMID: 26971415
- DOI: 10.1016/j.ejrad.2016.01.011
Assessment of PI-RADS v2 for the Detection of Prostate Cancer
Abstract
Purpose: To evaluate the diagnostic performance and inter-reader reliability of the multiparametric magnetic resonance imaging (mpMRI) based prostate imaging reporting and data system (PI-RADS) version 1 and version 2 for the assessment of prostate cancer.
Material and methods: A cohort of 82 patients underwent endorectal mpMRI at 1.5T. Patients had at least one lesion with a PI-RADS v1 assessment category of ≥3 and were selected for targeted in-bore MR-guided biopsy in a subsequent session. The results of the histopathological workup were used as reference standard. All lesions were retrospectively evaluated according to PI-RADS v2 by an experienced and unexperienced blinded reader. Diagnostic performance was compared by analyzing the area under the Receiver Operating Characteristics Curve (AUC). The weighted kappa method was used to calculate inter-reader reliability.
Results: Targeted MR-guided biopsy was performed in 136 lesions and revealed 39 malignant lesions in 31 patients. AUC values increased for the experienced reader (PI-RADS v1 0.79; PI-RADS v2 0.83) and unexperienced reader (PI-RADS v1 0.70; PI-RADS v2 0.83). When excluding the cases of low grade cancer (Gleason score=3+3), AUC values increased further for the experienced reader (PI-RADS v1 0.88; PI-RADS v2 0.91) and unexperienced reader (PI-RADS v1 0.78; PI-RADS v2 0.90). Specificity at the selected threshold of a PI-RADS v1/v2 assessment category ≥4 improved for both readers. Inter-reader agreement increased from κ=0.55 in PI-RADS v1 to κ=0.68 in v2.
Conclusion: PI-RADS v2 improved diagnostic performance for the assessment of suspicious intraprostatic lesions identified in PI-RADS v1 for both readers and led to higher inter-reader reliability. These results suggest that PI-RADS v2 is a reliable and replicable reporting system for the assessment of prostate cancer.
Keywords: Biopsy; ESUR; MRI; Prostate cancer.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Head-to-head comparison of PI-RADS v2 and PI-RADS v1.Eur J Radiol. 2016 Jun;85(6):1125-31. doi: 10.1016/j.ejrad.2016.03.025. Epub 2016 Mar 29. Eur J Radiol. 2016. PMID: 27161062
-
Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.Eur J Radiol. 2019 Jul;116:180-185. doi: 10.1016/j.ejrad.2019.04.012. Epub 2019 May 14. Eur J Radiol. 2019. PMID: 31153562
-
Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer.Eur J Radiol. 2019 Dec;121:108704. doi: 10.1016/j.ejrad.2019.108704. Epub 2019 Oct 17. Eur J Radiol. 2019. PMID: 31669798
-
Interobserver Agreement and Accuracy in Interpreting mpMRI of the Prostate: a Systematic Review.Curr Urol Rep. 2022 Jan;23(1):1-10. doi: 10.1007/s11934-022-01084-y. Epub 2022 Feb 28. Curr Urol Rep. 2022. PMID: 35226257 Review.
-
Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis.Eur Urol. 2015 Jun;67(6):1112-1121. doi: 10.1016/j.eururo.2014.10.033. Epub 2014 Nov 6. Eur Urol. 2015. PMID: 25466942 Review.
Cited by
-
Growth Patterns of Prostate Cancers Undetected by Prostate 3T Multiparametric MRI.In Vivo. 2024 Mar-Apr;38(2):833-841. doi: 10.21873/invivo.13508. In Vivo. 2024. PMID: 38418107 Free PMC article.
-
The Impact of Prostate Imaging Reporting and Data System Version 2.1 and Prostate-Specific Antigen Density in the Prediction of Clinically Significant Prostate Cancer.Urol Res Pract. 2023 Mar;49(2):120-124. doi: 10.5152/tud.2023.220199. Urol Res Pract. 2023. PMID: 37877859 Free PMC article.
-
Four-quadrant vector mapping of hybrid multidimensional MRI data for the diagnosis of prostate cancer.Med Phys. 2024 Mar;51(3):2057-2065. doi: 10.1002/mp.16687. Epub 2023 Aug 29. Med Phys. 2024. PMID: 37642562
-
The Evidence for Using Artificial Intelligence to Enhance Prostate Cancer MR Imaging.Curr Oncol Rep. 2023 Apr;25(4):243-250. doi: 10.1007/s11912-023-01371-y. Epub 2023 Feb 7. Curr Oncol Rep. 2023. PMID: 36749494 Review.
-
Artificial Intelligence for Clinical Diagnosis and Treatment of Prostate Cancer.Cancers (Basel). 2022 Nov 14;14(22):5595. doi: 10.3390/cancers14225595. Cancers (Basel). 2022. PMID: 36428686 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
